ArticleThe Laryngoscope2026
The Mental Health Impact of Retrograde Cricopharyngeus Dysfunction (RCPD) and Its Treatment.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Mental Health Impact of Retrograde Cricopharyngeus Dysfunction (RCPD) and Its Treatment.The Laryngoscope · 2026Article
- Outcomes in the Management of Pediatric Retrograde Cricopharyngeal Dysfunction.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRCPD is a condition characterized by the inability to belch. Our study aims to assess the prevalence of anxiety and depression within this population while evaluating the impact of cricopharyngeal botulinum toxin injection (CPBTI) on associated symptoms.
methodsRCPD patients selected for treatment with CPBTI were given three validated questionnaires for anxiety (GAD-7, ASQ) and depression (PHQ-9) before CPBTI, as well as 6 weeks and 6 months after. The changes were assessed with ANOVA, and minimal clinically important differences (MCID) of the surveys were used to qualify improvement in scores.
resultsSeventy-seven patients completed the pretreatment questionnaire. Of the 69 patients who ultimately received treatment, 45 completed at least one follow-up questionnaire and 32 completed all three. Mean age was 30.9% and 61% self-reported a diagnosed mental health comorbidity (MHC). GAD-7 identified at least mild anxiety in 73%, 50%, and 46% of patients at each timepoint, respectively. PHQ-9 identified at least mild depression in 68%, 52%, and 34%, respectively. Mean pretreatment, 6-week, and 6-month scores were 8.16, 5.04, and 4.4, respectively, for GAD-7 (p < 0.001); 7.87, 5.71, and 4.20, respectively, for PHQ-9 (p = 0.002); and 112.4, 75.6, and 65.20, respectively, for ASQ (p = 0.001). Using MCID values for GAD-7 and PHQ-9, 64% showed significant improvement in anxiety and 60% showed significant improvement in depression after treatment.
conclusionRCPD patients have a high prevalence of comorbid anxiety and depression. Treatment with CPBTI correlates strongly with a sustained reduction in these symptoms beyond the duration of botulinum toxin. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.